Understanding treatment
Immunotherapy side effects — what's different from chemo
Immune-related adverse events (irAEs) from cancer immunotherapy look different from chemo side effects. What to watch for, when to call your oncologist, and why it matters.
If your oncologist starts you on immunotherapy — a PD-1 inhibitor like pembrolizumab or nivolumab, a PD-L1 inhibitor like atezolizumab, a CTLA-4 inhibitor like ipilimumab, or a combination — the side effect profile is fundamentally different from chemotherapy.
Here’s what that means in plain language, and what to watch for.
How immunotherapy side effects are different
Chemotherapy mostly damages rapidly dividing cells, which is why it tends to cause predictable effects: hair loss, nausea, low blood counts, fatigue, mouth sores. Side effects usually happen during or shortly after infusion and improve between cycles.
Immunotherapy activates your immune system to attack cancer. The side effects — called immune-related adverse events (irAEs) — happen when your activated immune system also attacks healthy tissue. They can appear:
- Anywhere in the body — skin, gut, lungs, thyroid, liver, joints, heart, pituitary, kidneys, eyes
- At any time — weeks, months, or even after treatment ends
- Unpredictably — you can get through early cycles fine and have a major event later
Most irAEs are mild and managed with supportive care or a pause in treatment. Some are serious and require hospitalization and high-dose steroids. A small fraction are life-threatening.
The most common irAEs, roughly in order of frequency
Fatigue
Nonspecific but real. Baseline low energy is common on immunotherapy. Tell your oncologist if it worsens suddenly — could signal another irAE like thyroid or adrenal problems underneath.
Skin (rash, itching)
Very common. Usually mild. Can progress — watch for blistering, peeling, or mucous membrane involvement, which are signs to call your oncologist immediately.
Gut (colitis — diarrhea)
One of the most important to catch early. More than 4–6 bowel movements above your normal daily baseline, or any blood in stool, or severe abdominal pain — call your oncologist that day. Untreated immune colitis can cause bowel perforation.
Thyroid (hypothyroidism, sometimes hyperthyroidism first)
Symptoms: persistent fatigue, weight changes, cold or heat intolerance, mood changes. Your team should be checking thyroid labs regularly. Usually manageable with thyroid hormone replacement.
Lung (pneumonitis)
Less common but important. Symptoms: new cough, shortness of breath, chest tightness. Call your oncologist before your next scheduled appointment — do not wait for it. Pneumonitis is treated with steroids.
Liver (hepatitis)
Usually found on routine lab monitoring before you feel sick. Symptoms if advanced: nausea, jaundice, right upper abdominal pain.
Endocrine (pituitary, adrenal)
Less common but can be serious. Symptoms: severe fatigue, low blood pressure, unexplained nausea, headaches. Adrenal crisis is an emergency — call 911 if you have these symptoms and are severely ill.
Joint pain (arthralgia, arthritis)
Can be mild or severe. Worth mentioning at appointments, not emergency.
Heart (myocarditis — rare but serious)
Symptoms: chest pain, shortness of breath, palpitations, fatigue. Rare but the most lethal irAE when it happens. Any new cardiac symptoms warrant an ER visit.
When to call your oncologist versus go to the ER
Call your oncologist’s after-hours line:
- New fever >100.4°F / 38°C
- Diarrhea 4+ bowel movements above baseline, or any blood
- New shortness of breath or persistent cough
- Severe or worsening rash
- New severe joint pain or muscle weakness
Go to the ER (bring a list of your medications including the immunotherapy name):
- Chest pain or severe shortness of breath
- Confusion, severe headache, vision changes
- Severe abdominal pain
- Signs of adrenal crisis — collapse, severe fatigue with low blood pressure
- Any symptom your oncologist’s office tells you to go in for
Important: tell every ER doctor, urgent care provider, and primary care physician that you are on immunotherapy. Bring the drug name in writing. Many irAEs are missed because non-oncologists aren’t familiar with them.
Why oncologists don’t always stop treatment at the first side effect
With chemotherapy, reducing dose or pausing is often the first move. With immunotherapy, the paradigm is different:
- Mild irAEs (grade 1) — usually continue treatment with close monitoring
- Moderate irAEs (grade 2) — pause treatment, start steroids, usually restart when improved
- Severe irAEs (grade 3-4) — pause treatment, high-dose steroids, often hospitalize, restart only if the risk-benefit favors it
This is counterintuitive to patients. Your oncologist isn’t ignoring a side effect by continuing treatment — they’re following evidence-based grading.
What to track on your own
Keep a simple daily log (paper or phone notes) during immunotherapy:
- Bowel movements per day (yes, this matters)
- Any new skin changes, even mild
- Energy level 1–10
- Any new pain, cough, shortness of breath
- Temperature if you feel unwell
- Any new medication you’re taking (including OTC)
Bring the log to every appointment. Your oncologist spots trends you may not notice in the moment.
Does having side effects mean the drug is working?
There’s data suggesting patients who develop irAEs may have somewhat better response rates — but the correlation is modest, and no one should interpret lack of side effects as “it’s not working.” Don’t try to induce a side effect. Don’t stop a medication hoping to get one.
Related reading
- FDA-approved immunotherapy drugs by cancer type — each cancer page’s treatments section groups immunotherapy drugs together
- Cancer biomarkers explained (PD-L1, MSI, TMB) — biomarkers predict immunotherapy eligibility
- Questions to ask your oncologist — add specific questions about irAE monitoring
- How to request your medical records — useful when moving between providers
Sources and further reading
- NCI page on Checkpoint Inhibitors and Their Side Effects
- ASCO’s Management of Immune-Related Adverse Events practice guidelines
- NCCN’s patient-facing Managing Immunotherapy Side Effects PDF